Psychedelics

Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.

TSI EDITOR | 2021-10-20

---

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

Cybin has completed its 74th pre-clinical study and anticipates commencing human clinical studies in early 2022.

TSI EDITOR | 2021-10-19

---

COMPASS Pathways is granted new US patent for crystalline psilocybin

Compass Pathway's fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.

TSI EDITOR | 2021-10-19

---

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Field Trip is adding three new clinics to its network, with two of the three already open and the third opening imminently.

TSI EDITOR | 2021-10-19

---

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.

TSI EDITOR | 2021-10-19

---

Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions

Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.

TSI EDITOR | 2021-10-18

---

MindMed Joins Clinical Trials Transformation Initiative

MindMed joins the Clinical Trials Transformation Initiative, a forward-looking healthcare association that develops/promotes new health therapies.

TSI EDITOR | 2021-10-13

---

Novamind Granted DEA Licenses for Psilocybin Research

Novamind's new DEA licenses open up opportunities to host formal clinical trials.

TSI EDITOR | 2021-10-13

---

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher receives its second FDA orphan drug designation for a ketamine-based therapy.

TSI EDITOR | 2021-10-13

---

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

Cybin files a new patent application in support of the development of drug candidate CYB004.

TSI EDITOR | 2021-10-12

---

• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• ...
• 43
• Next